Lavie, D. Et Al. 2023. KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.. JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16 .

Lavie, D., Timmerman, J., Sanz, R. G., Kim, W. S., Kim, T. M., Avigdor, A., ... Dierickx, D.(2023). KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.. JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16.

Lavie, David Et Al. "KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.," JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16, 2023

Lavie, David Et Al. "KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.." JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16, 2023

Lavie, D. Et Al. (2023) . "KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.." JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16.

@article{article, author={David Lavie Et Al. }, title={KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2023}